Derrell Porter, serving as a director at Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), completed a series of stock transactions between June 15 and June 17, 2026, resulting in the sale of $75,239 worth of common shares. The disposal of shares occurred across three distinct dates, with transaction prices varying between $2.305 and $2.345 per share.
On June 15, 2026, Mr. Porter sold 6,460 shares at a price of $2.345 per share. The following day, June 16, he disposed of an additional 12,800 shares. These transactions were executed at a weighted average price of $2.326, with individual sale prices falling between $2.305 and $2.345. On June 17, Mr. Porter sold another 13,040 shares at a price of $2.325 per share. Following these sales, his direct holdings in Acumen Pharmaceuticals common stock stand at 35,500 shares.
Before executing the sales, Mr. Porter acquired the shares through the exercise of stock options. On June 15, he acquired 6,460 shares by exercising options at a price of $1.07 per share. He acquired an additional 13,040 shares on June 17 through option exercises, also at $1.07 per share. The total value of shares acquired through option exercises amounted to $20,865. These options vested in full on the date of the 2026 annual stockholder meeting and have an expiration date of June 4, 2035.
The sales occur as Acumen Pharmaceuticals shares have delivered an 88% return over the past year. Despite this recent performance, the stock currently trades below its InvestingPro Fair Value, suggesting potential upside. For deeper insights, including 7 additional ProTips and comprehensive analysis, investors can access the full Pro Research Report available exclusively on InvestingPro.
In other recent developments, Acumen Pharmaceuticals reported its earnings for the first quarter of 2026, surpassing analyst expectations. The company achieved an earnings per share (EPS) of -$0.33, compared to the anticipated -$0.37, marking a positive surprise of 10.81%. This development comes amid cautious investor sentiment, as reflected in pre-market trading activity. Additionally, Acumen Pharmaceuticals announced the nomination of two development candidates, ACU301 and ACU401, for Alzheimer's disease treatment. These candidates are part of the company's Enhanced Brain Delivery program and utilize amyloid beta oligomer-selective antibody technology in conjunction with JCR Pharmaceuticals' J-Brain Cargo platform. These recent developments highlight Acumen's ongoing efforts in advancing its treatment pipeline.
Is ABOS a bargain right now? The fastest way to find out is with our Fair Value calculator. We use a mix of 17 proven industry valuation models for maximum accuracy. Get the bottom line for ABOS plus thousands of other stocks and find your next hidden gem with massive upside. Flash Sale - Price Goes Up Soon